Related Experiment Video

Updated: Jun 20, 2026

Looking for Driver Pathways of Acquired Resistance to Targeted Therapy: Drug Resistant Subclone Generation and Sensitivity Restoring by Gene Knock-down
08:59

Looking for Driver Pathways of Acquired Resistance to Targeted Therapy: Drug Resistant Subclone Generation and Sensitivity Restoring by Gene Knock-down

Published on: December 11, 2017

The molecular genetics of breast cancer and targeted therapy

Rachel Suter1, James A Marcum

  • 1The University of Texas Medical Branch, Galveston, TX, USA.

Biologics : Targets & Therapy
|August 27, 2009
PubMed

Insights

Breast cancer is a complex molecular disease driven by altered cell growth pathways. Understanding these molecular alterations provides targets for effective breast cancer therapies and prevention strategies.

Area of Science:

  • Oncology
  • Molecular Biology
  • Genetics

Background:

  • Breast cancer is a complex molecular disease characterized by alterations in cellular pathways.
  • Key pathways involved in cell growth and proliferation include MAPK, RB/E2F, PI3K/AKT/mTOR, and TP53.
  • Numerous genes, including oncogenes (HER2, c-MYC, RAS), ER genes, cell cyclins (D1, E), tumor suppressors (RB, TP53, PTEN), and susceptibility genes (BRCA1, BRCA2), are altered in breast cancer.

Purpose of the Study:

  • To elucidate the molecular underpinnings of breast cancer.
  • To identify specific molecular targets for therapeutic intervention.
  • To explore the potential for developing effective prevention strategies based on molecular understanding.

Main Methods:

  • Analysis of molecular pathways involved in cell growth and proliferation.
  • Identification and characterization of altered genes in breast cancer.
  • Review of current understanding of breast cancer molecular biology.

Main Results:

  • Detailed description of altered cellular pathways (MAPK, RB/E2F, PI3K/AKT/mTOR, TP53) in breast cancer.
  • Identification of key genes (oncogenes, ER genes, cell cyclins, tumor suppressors, BRCA1/2) implicated in breast cancer development.
  • Elucidation of the complex molecular nature of breast cancer.

Conclusions:

  • The molecular complexity of breast cancer has historically challenged treatment and prevention.
  • Decades of research have elucidated critical molecular pathways and genes involved in breast cancer.
  • This molecular understanding is now paving the way for targeted therapies and future prevention strategies.
Keywords:
breast canceroncogenestargeted therapytumor suppressor genes

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase01:11

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...